Older adults and type 2 diabetes

Narrower target glucose range than currently recommended may produce the lowest cardiovascular and mortality risk in older Asian people with type 2 diabetes, say the authors of a real-world study.

Older people with and without diabetes experience similar short-term improvements in exercise capacity following cardiac rehabilitation, but those with diabetes fare worse after 1 year, EU-CaRE study results suggest.

Older adults with type 2 diabetes often receive diabetes medication adjustments at hospital discharge that may be of little or no benefit, study results suggest.

Measuring high-sensitivity cardiac troponins I and T can help to refine mortality risk prediction in older adults with diabetes and different levels of comorbidity burden, research shows.

Older patients with type 2 diabetes and multiple comorbidities continue to achieve lower glycated hemoglobin levels, often while on insulin, than their younger, healthier counterparts, despite guideline advice to the contrary, US researchers report.

The quality of care among older adults with diabetes declines with increasing comorbidity and is particularly low for those with both osteoarthritis and major depression, population-based study data show.

Prediabetes has no effect on the short-term mortality risk of older adults, suggests an analysis of the Atherosclerosis Risk in Communities study.

The effect of glycemic control on all‐cause mortality risk depends on diabetes duration in people aged 65 years and older with type 2 diabetes, study findings indicate.

Known sex differences among younger patients with type 2 diabetes persist among those aged 90 years and older, particularly optimal use of cardiovascular preventive therapies which is significantly less likely among women than men, Spanish research shows.

Older people with diabetes are frailer throughout aging than those without diabetes, study findings indicate.

Older type 2 diabetes patients receiving basal insulin treatment who switch to glargine 300 units/mL experience greater or similar improvements in glycemic control compared with those switching to a first-generation basal insulin, with lower hypoglycemia risk, researchers report.

Older people starting treatment with sodium-glucose cotransporter 2 inhibitors have a lower risk for hospitalization for heart failure than those starting glucagon-like peptide-1 receptor agonists, research shows.

A prospective study reveals accelerated declines in some measures of cognitive performance among people with type 2 diabetes.

The addition of empagliflozin reduces nighttime blood pressure in older diabetes patients who have nocturnal hypertension despite medication including angiotensin receptor blockers, show findings from a randomized trial.

The LEADER investigators report that treatment with the glucagon-like peptide-1 receptor agonist liraglutide may be of particular benefit in the oldest patients with type 2 diabetes.

An increase in depressive symptoms around the time of a new diabetes diagnosis in older adults is associated with increasing difficulty in performing daily activities such as shopping, walking, and dressing, US researchers report.

Research shows an increased mortality risk associated with the use of intensive antidiabetes treatments in older patients with type 2 diabetes.

Insulin titration benefits individuals with type 2 diabetes regardless of age or whether it is self- or physician-managed, according to data presented at the ADA’s 78th Scientific Sessions in Orlando, Florida, USA.

Degludec delivers the same magnitude of protection against hypoglycemia relative to glargine across patient age groups, shows analysis of the SWITCH 2 and DEVOTE trials.

The excess mortality risk associated with high or very low glycated hemoglobin values is modified by glycemic variability in diabetes patients aged 70 years or more, shows an analysis of The Health Improvement Network database.